This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Merck Asks FDA to Authorize Promising Covid-19 Pill
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Merck Asks FDA to Authorize Promising Covid-19 Pill
Business

Merck Asks FDA to Authorize Promising Covid-19 Pill

Editorial Board Published October 11, 2021
Share
Merck Asks FDA to Authorize Promising Covid-19 Pill
SHARE

Merck & Co. and partner Ridgeback Biotherapeutics LP said Monday they have filed an application asking U.S. health regulators to authorize their Covid-19 pill, the next step toward adding a long-sought drug for use at home.

Contents
Newsletter Sign-upCoronavirus Briefing and Health WeeklyCovid-19 Vaccines

The filing comes shortly after data from a late-stage study showed that the antiviral drug, molnupiravir, cut the risk of hospitalization or death by about 50% in high-risk people with mild to moderate Covid-19. 

The U.S. Food and Drug Administration could clear the antiviral in the coming weeks and possibly in time for what some public-health experts say could be another virulent winter, especially among people who aren’t vaccinated.

“The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” Merck Chief Executive Robert Davis said.

Unlike Covid-19 vaccines and some other drugs for the disease that target the spike protein, molnupiravir works by targeting a part of the virus that helps it reproduce.


Newsletter Sign-up

Coronavirus Briefing and Health Weekly

Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.


Doctors and patients have been waiting for an effective pill that would be easy to take at home, with the goal of preventing a case from turning severe and requiring hospitalization.

Antibody drugs, like one from Regeneron Pharmaceuticals Inc., have been authorized for use in Covid-19 patients before they are hospitalized. These drugs have shown to be more effective in clinical trials, but they require infusions and are tougher to administer.

The Merck-Ridgeback pill, if authorized, would be the first oral antiviral for Covid-19. A course of treatment is 40 pills, eight daily for five days, started within five days of showing symptoms.

The companies have said that the rate of side effects in study subjects who got molnupiravir and those who got a placebo was similar.

The findings were based on an early look at the data from a pivotal trial that is scheduled to finish in November.

Merck plans to manufacture 10 million courses of treatment by the end of the year and has already begun production. The Kenilworth, N.J.-based drugmaker has a $1.2 billion deal with the U.S. to provide 1.7 million courses of treatment, should regulators clear it for use.

Merck also has said it would make molnupiravir available globally and has licensing agreements with generic drugmakers, including Dr. Reddy’s Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. , to ensure the drug’s availability to low-income countries.

The company also said it plans to peg pricing for molnupiravir to the wealth of the country buying it, based on World Bank criteria, to help expand access to low- and middle-income countries.

Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ

Remdesivir, from Gilead Sciences Inc., is the only FDA-approved antiviral but its use is restricted to hospitalized patients.

The companies announced molnupiravir’s positive results this month after an early look at the data found that it helped unvaccinated people who were at high risk of becoming sick. High risk was defined as having at least one characteristic associated with severe disease or death, such as old age, obesity or diabetes.

The emergency-use authorization requested by Merck and Ridgeback is different from a full approval, permitting manufacturers to distribute products during public-health emergencies based on the best available evidence at the time.

Ridgeback licensed molnupiravir from a not-for-profit biotech company owned by Emory University and last year joined with Merck on its development.

Other drugmakers are working on Covid-19 antivirals, including Roche Holding AG and partner Atea Pharmaceuticals Inc., as well as Pfizer Inc., though they haven’t yet announced any results from late-stage studies.

Covid-19 Vaccines

Write to Jared S. Hopkins at jared.hopkins@wsj.com

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article The Latest Slump in Car Sales Has Winners and Losers The Latest Slump in Car Sales Has Winners and Losers
Next Article Bing Crosby’s heirs sell stake in estate to boost his work Bing Crosby’s heirs sell stake in estate to boost his work

Editor's Pick

JPMorgan unveils its 2025 summer season studying record

JPMorgan unveils its 2025 summer season studying record

JPMorgan Chase Chairman and CEO Jamie Dimon on the significance of management abilities, deregulation coverage, power independence and the Federal…

By Editorial Board 4 Min Read
Overview: Hollywood star delivers an enormous shock at BottleRock Napa
Overview: Hollywood star delivers an enormous shock at BottleRock Napa

Followers turned out to see Kate Hudson at BottleRock Napa Valley on…

5 Min Read
Man shot and killed on one hundredth Avenue in Oakland on Saturday
Man shot and killed on one hundredth Avenue in Oakland on Saturday

Oakland police are investigating the loss of life of a person, 34,…

1 Min Read

Oponion

Multi household sells in Palo Alto for .1 million

Multi household sells in Palo Alto for $2.1 million

Bay Space House Report 3277 Alma Avenue – Google Avenue…

November 4, 2024

Airbnb unveils new co-host community to spice up variety of listings on platform

Airbnb co-founder and CEO Brian Chesky…

October 16, 2024

Eggs usually are not the one costly meals: beef costs are additionally on the rise

Pat LaFrieda Meat Purveyors CEO Pat…

February 27, 2025

‘Insulted PM Modi’: BJP Slams Tamil Nadu CM Stalin For Skipping Rameswaram Occasion

Final Up to date:April 06, 2025,…

April 6, 2025

Harriette Cole: A woman in school is spreading lies about my sister

DEAR HARRIETTE: This lady in school,…

November 8, 2024

You Might Also Like

Omnispace, Gatehouse Satcom and Nordic Semiconductor Exhibit 5G NB-IoT Functionality over Non-Geostationary S-band Satellite tv for pc
Business

Omnispace, Gatehouse Satcom and Nordic Semiconductor Exhibit 5G NB-IoT Functionality over Non-Geostationary S-band Satellite tv for pc

Omnispace, Gatehouse Satcom, and Nordic Semiconductor, at the moment introduced the profitable demonstration of a 5G narrowband Web of Issues…

3 Min Read
74% of asset monitoring initiatives meet or exceed ROI expectations
Business

74% of asset monitoring initiatives meet or exceed ROI expectations

Companies adopting IoT asset monitoring options prioritize wonderful vendor help and seamless integration capabilities over an intensive checklist of options,…

2 Min Read
Iridium and Syniverse Companion to Convey Direct-to-Gadget Satellite tv for pc Connectivity to Cellular Community Operators Worldwide
Business

Iridium and Syniverse Companion to Convey Direct-to-Gadget Satellite tv for pc Connectivity to Cellular Community Operators Worldwide

Iridium Communications Inc., a number one supplier of world voice and knowledge satellite tv for pc communications, right now introduced…

3 Min Read
3 Modern Methods Healthcare Companies Use Tech To Enhance The Affected person Expertise
Business

3 Modern Methods Healthcare Companies Use Tech To Enhance The Affected person Expertise

The healthcare trade is among the largest proponents of know-how use all through the office. It’s an trade stuffed with…

4 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?